|
Workshop
[In-Person] Oncology Clinical Dose Optimization in Light of FDA Project Optimus
Speakers:
Stacy Shord, FDA; Harald A.Weber, Seagen/Pfizer; Patrick Williams, Genentech; Donghua Yin, Pfizer; Peter C Trask, Genentech; Shelly Wang; Divya Samineni, Genentech
Organizers:
Chunze Li, Jesse Yu, Joseph Chen (Department of Clinical Pharmacology, Genentech)
Date:
2024-04-26
Time:
8:45-17:00 Pacific Time
Registration fee:
Regular attendees: $295; Academic/Students/Postdocs: $45; Out-of-Pocket: $45; Major Sponsorship: $3000; Vendor Show: $695, Happy Hour Sponsorship: $975; Lunch Sponsorship: $1250; On-site Registration: $500
Location:
Crowne Plaza, Foster City, CA (San Francisco Bay Area)
Major Sponsor:
Vendor show vendors registered to date:
(2)BioAgilytix; Meadowhawk Biolabs
Registration: http://www.PBSS.org
Registration deadline:2024-04-24
(it will close sooner if the seating cap is reached)
About the Topic
Historically, dose selection in oncology was driven by the MTD paradigm. This traditional approach was partly driven by the few available therapies in oncology, and the need to bring effective drugs to the market as soon as possible. Now that the field of oncology drug development has matured and cancer patients are living longer than ever on chronic therapies, we as drug developers need to meet these new challenges by shifting our approach to oncology dose selection to a new paradigm. This one-day workshop will discuss the new regulatory expectations to oncology dose selection, various approaches to optimize oncology dose selection from a study design as well as statistical perspective, different clinical pharmacology considerations and related analysis to support dose selection, and evaluations using patient-reported outcomes. About the Speakers
Time (PST)
|
Topic
|
Presenter
|
8:45 - 9:00 am
|
PBSS Welcome and Introduction
|
Shichang Miao (PBSS)
|
9:00 - 9:30 am
|
FDA Embracing Innovation for Dosage Optimization of Oncology Products
|
Stacy Shord, Deputy Division Director, FDA
|
9:30 - 10:10 am
|
Clinical consideration for Oncology dose optimization
|
Harald A.Weber, MD, Executive Medical Director, Seagen/Pfizer
|
10:10 - 10:20 am
|
Major Sponsor Presentation
|
Allucent |
10:20 - 10:40 am
|
Break and Vendor Show
|
-
|
10:40 - 11:20 am
|
Oncology dose finding CDP for different molecule classes
|
Patrick Williams, MD, Senior Medical Director, Genentech
|
11:20 - 11:50 am
|
Biostatistic consideration and adaptive designs for oncology dose finding
|
Hao Wang, PhD, Director, Clinical Data Science-Biostatistics, Gilead
|
11:50am-12:30 pm
|
Clinical pharmacology considerations towards efficient oncology dose finding
|
Donghua Yin, PhD, VP, Pfizer
|
12:30 - 1:20 pm
|
Lunch
|
Sponsor (TBD) |
1:20 - 2:00 pm
|
Patient reported outcome for oncology dose optimization
|
Peter C Trask, Ph.D., MPH Senior Director, Head of Oncology, Patient-Centered Outcomes Research, Genentech
|
2:00 - 2:40 pm
|
Population PK, covariates characterization, and E-R for dose selection
|
Shelly Wang, Ph.D.
|
2:40 - 2:50 pm
|
Major Sponsor Presentation
|
Olink Proteomics |
2:50 - 3:15 pm
|
Break and Vendor Show
|
-
|
3:15 - 3:50 pm
|
Oncology dose optimization - IQ consortium perspectives
|
Divya Samineni, PhD, Distinguished Scientist, Genentech
|
3:50 - 4:30 pm
|
Panel Discussion and Q&A
|
All Speakers
|
4:30 - 5:30 pm
|
Happy Hour
|
Sponsor (TBD)
|
2024-08-14, [Free Online] Advances in Cancer Therapeutics (Organized by PBSS and BioScience Forum)
|
2024-08-22, [Free Online] Diabetes and Obesity Treatments: Current and Emerging Landscapes of GLP-1, GIP, and Beyond
|
2024-09-10, [In-Person] Translational PK/PD and Human Dose Projection for Antibodies/ADCs and Novel Therapeutic Modalities
|
2024-09-20, [In-Person] Nonclinical Safety Assessments of Biologics and Other Novel Modalities for IND/NDA/BLA Filings
|
2024-09-25, [Free Online] Development of Protein Degraders: Computational Modeling, Medicinal Chemistry and Early Development
|
2024-10-10, [In-Person] Regulatory Global Submission: Strategies and Best Practices for FDA, EMA and PMDA
|
2024-10-25, [Free Online Workshop] Unleashing the Power of Real-World Evidence / Data (RWE/RWD) to Facilitate Drug Discovery, Development, and Beyond
|
2024-11-01, [In-Person] Clinical Pharmacology Studies on Hepatic and Renal Impairments for NDA Filing: Strategies, Design, Conduct, Analysis and Regulatory Aspects
|
2024-11-13, [Free Online Workshop] Career Transition for Research Scientists: Business Development & BioPartnering
|
2024-11-15, [In-Person] Bioanalysis for Biologics and Cell/Gene Therapy Products: Refining Established Approaches for New Complex Therapeutics
|
2025-01-22, [In-Person] Small-Molecule Formulation for Discovery & Early Development (jointly by PBSS / AAPS-BADG / Syner-G)
|
|
Ads (in random order)
Submit a Text Ad ($250 for 2 months)
Simulations Plus
GastroPlus X: Science, models & refined algorithms—now with intuitive interface, faster processing & streamlined workflows for faster PBPK modeling.
|
Alturas Analytics, Inc.
Expert Regulated & Non-Regulated LC-MS, GC-MS bioanalytical & PK/TK analysis of small & large molecules in any matrix. Discovery through phase IV.
|
Submit a Text Ad
|